Search clinical trials for: valsartan, fluvastatin

Total 586 results

Novartis

Completed

Efficacy and Safety of Fluvastatin or Valsartan and Their Combination in Dyslipidemic Patients With Hypertension and Endothelial Dysfunction

Hypertension | Dyslipidemia

Russian Federation
Kitasato University
Yokohama City University Medical Center; St. Marianna University School of... and other collaborators

Unknown

Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension

Hypertension | Type 2 Diabetes Mellitus

Japan
AORTICA Group

Terminated

Randomized Study to Evaluate the Efficacy of Fluvastatin on Inflammatory Markers in Patients With Aortic Stenosis.

Aortic Valve Stenosis

Spain
Novartis

Completed

Efficacy and Safety of Fluvastatin in Different Doses in Adults With Mixed Dyslipidemia or Primary Hypercholesterolemia

Hypercholesterolemia | Mixed Dyslipidemia

China
Novartis

Completed

Other Effects of Fluvastatin Are Investigated in Patients With Metabolic Syndrome

Metabolic Syndrome

Germany
Novartis

Completed

Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia

Mixed Dyslipidemia | Heterozygous Familial Hypercholesterolemia

Switzerland
Novartis Pharmaceuticals

Completed

The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients (TurkuPET)

Heart Failure

Finland
Novartis Pharmaceuticals

Completed

Evaluation of the Effect of Fluvastatin 40 mg (b.i.d.) in the Prevention of the Development of Vasculopathy of the Graft in de Novo Renal Transplant Patients Transplant

Graft Vasculopathy

Spain
Bader, Ted, M.D.
US Department of Veterans Affairs

Completed

Fluvastatin Versus Hepatitis C Virus

Hepatitis C

United States
University Medical Centre Ljubljana

Completed

Preventive Arterial Wall Phenotype and Low-dose Fluvastatin/Valsartan Combination (AGE-ZT)

Atherosclerosis
Novartis

Completed

Trial to Evaluate the Efficacy of Fluvastatin on Certain Markers

Dyslipidemia

Spain
The Cleveland Clinic

Withdrawn

Comparison of ARNI to Alternate Oral Vasodilator Therapies in Patients With Low Cardiac Output (PARAVLO-HF)

Cardiogenic Shock

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Lipid Metabolism Disorders

China
University Medical Centre Ljubljana

Completed

Post- Myocardial Infarction Arterial Wall Improvement by Low-dose Fluvastatin and Valsartan

Myocardial Infarction

Slovenia
University of Zurich
University of Basel

Completed

Effect of Fluvastatin on Brown Fat Activity (FluvaBAT)

Insulin Resistance | Clinical Trial | Adipose Tissue, Brown

Switzerland
University of Bologna

Unknown

Fluvastatin After Heart Transplantation

Hypercholesterolemia | Heart Transplantation

Italy
Novartis

Completed

The Effect of Fluvastatin XL® Treatment in Patients With Metabolic Syndrome

Metabolic Syndrome

Turkey
Case Comprehensive Cancer Center

Withdrawn

Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas

Malignant Melanoma
Eli Lilly and Company

Completed

A Study of LY3015014 in Participants With High Cholesterol

Hypercholesterolemia

Poland, Netherlands, United States, Denmark, Canada, Japan, Czechia, Puerto Rico
Mario Negri Institute for Pharmacological Research

Completed

Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome

Alport Syndrome

Italy
University Hospital Schleswig-Holstein

Terminated

Cranoc Lipid Study in Renal Transplantation

Renal Transplantation

Germany
Organon and Co

Completed

A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808)

Hypercholesterolemia
Hospital for Special Surgery, New York
University of Texas

Completed

Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients

Antiphospholipid Syndrome

United States
Novartis

Completed

Fluvastatin in Adults With Dislipidemia With History of Muscle Problems

Dyslipidemia

Germany, United States
Novartis
Ministry of Health, Czech Republic

Completed

Fluvastatin in the Therapy of Acute Coronary Syndrome

Myocardial Infarction | Coronary Disease

Czech Republic
Martin-Luther-Universität Halle-Wittenberg
Novartis

Terminated

The Role of the "Inflammatory/ Pathogen Burden" for Cardiac Ageing (AntiCardAgeing)

Inflammation | Aging

Germany
University of California, San Francisco
National Cancer Institute (NCI)

Completed

Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer

Breast Cancer

United States
University of Leipzig
Novartis

Unknown

Statin Therapy in Asymptomatic Aortic Stenosis

Aortic Valve Stenosis

Germany
University Hospital, Saarland
Novartis

Withdrawn

Improvement of Erectile Dysfunction by Fluvastatin in Patients With Cardiovascular Risk Factors

Impotence

Germany
Mario Negri Institute for Pharmacological Research

Completed

Statins in Proteinuric Nephropathies (ESPLANADE)

Hypertension | Proteinuria | Chronic Nephropathy

Italy
Medical University of Graz

Completed

Fluvastatin 80 mg Ret. vs Combination With Ezetimibe 10 mg in Patients With High Cardiovascular Risk

Hypercholesterolemia

Austria
Qingdao Central Hospital

Not yet recruiting

Sacubitril/Valsartan Versus Valsartan for Hypertensive Patients With Acute Myocardial Infarction

Myocardial Infarction | Hypertension

China
University Health Network, Toronto

Completed

Novel Window of Opportunity Trial to Evaluate the Impact of Statins to Oppose Prostate Cancer

Prostate Cancer

Canada
Novartis

Completed

Reducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome (LesScore)

Hypertension, Dyslypidaemia
Damanhour University
Tanta University

Completed

Sacubitril/Valsartan Versus Valsartan in Heart Failure

Heart Failure

Egypt
Yuhan Corporation

Completed

Pharmacokinetic Drug Interaction Between Rosuvastatin and Valsartan

Hypertension | Hyperlipidemia

Korea, Republic of
Novartis Pharmaceuticals

Completed

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

Heart Failure With Preserved Ejection Fraction (HFpEF)

United States, Canada
Beijing Anzhen Hospital
Novartis

Unknown

Fluvastatin AmelIorates aTHerosclerosis Study (FAITH)

Atherosclerosis | Coronary Heart Disease

China
The Canadian College of Naturopathic Medicine
Canada Post Corporation; Canadian Union of Postal Workers

Completed

Naturopathic Treatment for the Prevention of Cardiovascular Disease (Cardio pilot)

Cardiovascular Disease

Canada
University of Alabama at Birmingham
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals

Cardiovascular Diseases | Diabetes Mellitus | Insulin Sensitivity/Resistance | Metabolic Disease | Energy Expenditure | Metabolism | Natriuretic Peptides

United States
Novartis Pharmaceuticals

Completed

Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure

Hypertension

Sweden, Belgium, Hungary, India, Italy, Poland, Turkey, United States, Brazil, France, South Africa
University of Alabama at Birmingham
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis (PRECISION-BP)

Cardiovascular Diseases | Hypertension | Obesity | Nocturnal Blood Pressure | Natriuretic Peptides | Renin-Angiotensin-Aldosterone System

United States
Novartis Pharmaceuticals

Completed

Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications (Navigator)

Diabetes Mellitus, Type 2

Austria, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, Denmark, Ecuador, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Italy, Malaysia, Mexico, Netherlands, Norway, Peru, Poland, Russian Federation and more
Forest Laboratories

Completed

Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension

Stage 2 Hypertension | Stage 1 Hypertension

United States
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease

Diabetic Kidney Disease

China
Novartis

Completed

Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP)

Hypertension
Viatris Inc.

Not yet recruiting

A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions

Chronic Heart Failure
Hannover Medical School
DLR German Aerospace Center

Withdrawn

Influences of Angiotensin-neprilysin Inhibition on Sympathetic Activity in Heart Failure (ARNI-Sy)

Heart Failure

Germany
The Children's Hospital of Zhejiang University...

Unknown

Study on the Treatment of Children With Purpura Nephritis With Huaiqihuang Granules

Henoch Schönlein Purpura Nephritis

China
Kitakyushu-Tsuyazaki Hospital

Completed

Valsartan Optimal Therapy Against Elevated Home Blood Pressure Research（VOYAGER）Study

Hypertension

Japan

Search clinical trials for: valsartan, fluvastatin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bangladesh

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations